Drugs / recombinant human brain natriuretic peptide
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase not applicable3 trials | ||||||
| — | NCT06745206 | Dec 2025 → Jun 2026 overdue | cardiomyopathy | Sichuan Provincial People's Hospital | Not yet recruiting | No outcome recorded |
| — | NCT05111769 | Dec 2021 → Dec 2023 | infectious disease with sepsis | Shanghai Zhongshan Hospital | Unknown | No outcome recorded |
| — | NCT01941576 | Sep 2013 → Dec 2017 | congenital heart defects, multiple types, tetralogy of fallot | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT05716984 Comparator | Apr → Dec 2023 | pulmonary hypertension | Shengjing Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Human Brain Natriuretic Peptide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06745206 ↗ |
| Known as | rhBNP | “Patients are first given a loading dose of recombinant human brain natriuretic peptide (rhBNP) 1.5 mcg/kg, followed by continuous infusion recombinant human brain natriuretic...” NCT01941576 ↗3“Recombinant human brain natriuretic peptide (rhBNP) is a biological agent with a molecular weight of 3664Da synthesized by DNA technology.” NCT05716984 ↗ “Recombinant human brain natriuretic peptide (rhBNP) was approved by FDA in 2001 for the treatment of acute decompensated heart failure.” NCT05111769 ↗ “recombinant human brain natriuretic peptide (rh-BNP) in this population” PMID 42192636 ↗ May 2026 |
| Modality | Peptide | “recombinant human brain natriuretic peptide (rhBNP)” NCT01941576 ↗ |
| Route | Other | “continuous infusion recombinant human brain natriuretic peptide 0.01-0.01mcg/kg/min for 72 hours.” NCT01941576 ↗ |